The most popular content from our Asembia coverage largely covered biosimilars.
While Asembia’s 2023 Specialty Pharmacy Summit covered a wide range of topics, including addressing health equity concerns within practices, updates on the specialty pharmacy pipeline, and policy discussions, biosimilars ultimately took center stage, according to the top content from The American Journal of Managed Care®’s Asembia coverage.
Here is the top coverage from Asembia, which was held April 30-May 4 in Las Vegas, Nevada, and check out all of our coverage.
5. How Are Health Care Organizations Working on DEI Efforts?
Inequitable care and health care deserts are well-known issues in the United States, and how to solve these health equity problems and improve internal diversity, equity, and inclusions initiatives were the main focus of this session from Asembia. Bansi Nagji, president of health care at GoodRx, gave a presentation on the topic, followed by a panel discussion, in which he was joined by Preeti Parikh, MD, practicing physician and executive medical director at GoodRx, and Pierre Theodore, MD, executive director of health equity at Genentech. The panel discussion covered what is currently being done and future focus.
4. Julie Reed: The Status Quo for Biosimilars Needs to Change to Maintain the Industry
Juliana (Julie) Reed, executive director of the Biosimilars Forum, discussed the challenges still facing the biosimilars industry and how they may impact the success of adalimumab biosimilars in the United States during a presentation at the meeting. She emphasized that biosimilars can play a role in addressing health equity issues since women, seniors, and low-income patients benefit the most from biosimilar competition. Reed also covered payer challenges that are limiting market competition and access to biosimilars.
3. An Overview of the Specialty Therapy Pipeline in 2023
The specialty pipeline has been growing year over year, and it’s projected to grow another 8% per year through 2025, noted Ray Tancredi, divisional vice president at Walgreens. In his presentation at Asembia, he highlighted 6 major trends in the specialty drug pipeline: innovation, gene and cell therapy, oncology therapies, patient centricity, biosimilars, and rare disease therapies.
2. Survey Shows Payers More Likely to Prefer Multiple Biosimilars for the Same Reference Product
During session, speakers reported that payers are more likely to prefer multiple biosimilars for the same reference product rather than just prefer 1 biosimilar or just the reference product. The presenters were Tasmina Hydery, PharmD, MBA, BCGP, associate director of digital solutions at AmerisourceBergen, and Cate Lockhart, PharmD, PhD, executive director of the Biologics and Biosimilars Collective Intelligence Consortium. They reviewed the current biosimilars landscape, discussed how payers view biosimilars at present and how biosimilars are being operationalized, and reviewed current pieces of legislation that are affecting biosimilar adoption.
1. Dr Fran Gregory Discusses the Implications of a New Wave of Biosimilars
During an interview at Asembia, Fran Gregory, PharmD, vice president of emerging therapies at Cardinal Health, discussed how biosimilars increase accessibility to medications for patients. She talked about the second wave of biosimilars, starting with the adalimumab biosimilars in 2023, hitting the market and the importance in the context of specialty pharmacy. It’ll be important for specialty pharmacies to understand the patient assistance programs and any financial support that is available for biosimilars as they did with many of these reference products, Gregory explained.
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fall
April 25th 2024The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
What We’re Reading: Abortion Privacy Rules; Alzheimer Drug Hurdles; Nursing Home Staffing Overhaul
April 23rd 2024New health privacy rules aim to protect patients and providers in an evolving abortion landscape; some physicians express concerns about efficacy, risks, and entrenched beliefs in treating Alzheimer disease; CMS addresses longstanding staffing deficits in nursing homes.
Read More
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More